Establishment of an ovarian malignant tumor organoid biobank

Background The heterogeneity of ovarian malignant tumors leads to large differences in individual patient outcomes, and classical treatment protocols are unable to achieve individualized treatment. The in vitro model of ovarian malignancy can be used as a substitute for patients for research and drug sensitivity assays, and the results may provide new clues for precision treatment of patients with ovarian malignancy.

Objective To establish a biobank of ovarian malignant tumor organoids, validate the consistency of the organoids with the corresponding ovarian cancer tissues at the genomic level, and explore the feasibility of predicting clinical efficacy with the drug sensitivity results of organoid models.

Methods Ovarian malignant tumor cells derived from patient tissues were isolated and cultured in a matrigel 3D environment to form organoids. The genomic characteristics of the organoid and the corresponding ovarian malignant tumor tissues were detected and compared using whole-exome sequencing. The organoid was cultured for 2-3 days and then added to chemotherapeutic drug or drug combination regimen for drug sensitivity determination.

Results A biobank of ovarian malignant tumor organoids was established in this study, containing 122 organoids from 113 patients, with a culture success rate of 90.4%. Whole-exome sequencing analysis showed that the ovarian malignant tumor organoids were consistent with the parental tumor tissues at the genomic level. The drug sensitivity results of ovarian malignant tumor organoids predicted clinical efficacy with an accuracy of 70.7%, a sensitivity of 75% and a specificity of 55.6%.

Conclusion In this study, a biobank of ovarian malignant tumor organoids has been successfully established in vitro, and the organoid model can reflect the genomic characteristics of the parental tumor, and its drug sensitivity results can reflect the clinical efficacy. The ovarian malignant tumor organoid biobank provides a reliable preclinical model for ovarian malignant tumour research, drug development and clinical treatment protocol formulation.